<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02711033</url>
  </required_header>
  <id_info>
    <org_study_id>GDPHCM-GI-01</org_study_id>
    <nct_id>NCT02711033</nct_id>
  </id_info>
  <brief_title>Laparoscopic-assisted Total Gastrectomy Versus Open Total Gastrectomy With Splenic Hilum Lymph Nodes Dissection</brief_title>
  <official_title>Laparoscopic-assisted Total Gastrectomy Versus Open Total Gastrectomy With Spleen-preserving Splenic Hilum Lymph Nodes Dissection for Advanced Proximal Gastric Cancer: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong Provincial Hospital of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangdong Provincial Hospital of Traditional Chinese Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates the safety and feasibility of laparoscopic-assisted total gastrectomy
      with spleen-preserving splenic hilum lymph node dissection for proximal advanced gastric
      cancer and compares the early results of this procedure with open total gastrectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For advanced proximal gastric cancer, total gastrectomy with D2 lymphadenectomy is the
      standard surgical therapy. Apparently, lymph nodes (LNs) dissection along the splenic artery
      (No.11) and the splenic hilum (No.10) is recommended by the Japanese Gastric Cancer Treatment
      Guidelines. Nevertheless, complete removal of the No. 10 and No. 11d LNs is technically
      challenging due to the tortuous splenic vessels and the high possibility of injury to the
      parenchyma of the spleen and pancreas. Recently, the application of minimally invasive
      surgery for advanced gastric cancer is gaining popularity. However, laparoscopic-assisted
      total gastrectomy (LATG) with standard D2 lymphadenectomy was still not widely performed,
      because pancreas- and spleen-preserving splenic hilum lymph node dissection were mainly
      challenging manipulations for laparoscopic surgeons. Herein, we aim to investigate the safety
      and feasibility of LATG with spleen-preserving splenic hilum lymph node dissection for
      proximal advanced gastric cancer and compares the early results of this procedure with open
      total gastrectomy (OTG).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Anticipated">April 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Early complication rate</measure>
    <time_frame>30 days</time_frame>
    <description>The early complication rate is defined as the event observed during operation and within 30 days after surgery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Operative time</measure>
    <time_frame>Intraoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of splenic hilum lymph nodes dissection</measure>
    <time_frame>Intraoperative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Operative blood loss</measure>
    <time_frame>Intraoperative</time_frame>
    <description>It will be assessed with the unit of &quot;ml&quot;.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incision length</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of total lymph nodes harvested</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of group No.10 lymph nodes harvested</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of lymph nodes posterior to splenic vessel</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Poster-operative recovery course</measure>
    <time_frame>30 days</time_frame>
    <description>Time to first ambulation, flatus, liquid diet and duration of hospital stay are used to assess the postoperative recovery course.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>3-year disease free survival rate</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>5-year overall survival rate</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metastasis rate of lymph nodes posterior to splenic vessel</measure>
    <time_frame>7 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>Splenic Hilum Lymph Nodes Dissection</condition>
  <condition>Total Gastrectomy</condition>
  <arm_group>
    <arm_group_label>Laparoscopic-assisted total gastrectomy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients including in the laparoscopic-assisted total gastrectomy (LATG) group will undergo LATG with spleen-preserving splenic hilum lymph nodes dissection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open total gastrectomy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients who are included in the open total gastrectomy (OTG) group will OTG with spleen-preserving splenic hilum lymph nodes dissection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic-assisted total gastrectomy</intervention_name>
    <description>When patients with advanced proximal gastric cancer are randomized in the laparoscopic-assisted total gastrectomy (LATG) group, they will received LATG with spleen-preserving splenic hilum lymph nodes dissection.</description>
    <arm_group_label>Laparoscopic-assisted total gastrectomy</arm_group_label>
    <other_name>LATG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Open total gastrectomy</intervention_name>
    <description>When patients with advanced proximal gastric cancer are randomized in the open total gastrectomy (OTG) group, they will received OTG with spleen-preserving splenic hilum lymph nodes dissection.</description>
    <arm_group_label>Open total gastrectomy</arm_group_label>
    <other_name>OTG</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with advanced proximal gastric cancer （T2-T4a,N0-N3,M0）

          -  Informed consent

          -  Eastern Cooperative Oncology Group (ECOG): 0 ot 1

          -  American Society of Anesthesiologists （ASA） score: Ⅰto Ⅲ

        Exclusion Criteria:

          -  Pregnancy or female in suckling period

          -  Contraindication to general anesthesia (severe cardiac and/or pulmonary disease)

          -  Severe mental disease

          -  Emergency operation due to complication (bleeding, perforation or obstruction) caused
             by primary tumor

          -  Body mass index (BMI) &gt; 30 kg/m2
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Wang, M.D., PH.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong Province Hospital of Chinese Medicine, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wei Wang, M.D., PH.D.</last_name>
    <phone>+86-13922255515</phone>
    <email>wangwei16400@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guangdong Province Hospital of Chinese Medicine, the Second Affiliated Hospital of Guangzhou University of Chinese Medicine</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Wang, M.D.,PH.D.</last_name>
      <phone>+86-13922255515</phone>
      <email>wangwei16400@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Wenjun Xiong, M.D.</last_name>
      <phone>+86-15920553177</phone>
      <email>xiongwj1988@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Wei Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jin Wan</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wenjun Xiong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 9, 2016</study_first_submitted>
  <study_first_submitted_qc>March 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2016</study_first_posted>
  <last_update_submitted>April 7, 2017</last_update_submitted>
  <last_update_submitted_qc>April 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangdong Provincial Hospital of Traditional Chinese Medicine</investigator_affiliation>
    <investigator_full_name>Wei Wang</investigator_full_name>
    <investigator_title>M.D., PhD.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

